

HEAD AND NECK DISEASE SITE COMMITTEE

VIRTUAL SPRING MEETING
SUNDAY MAY 1ST, 2022, 10:00 AM – 02:00 PM

CHAIR: JOHN WALDRON
SENIOR INVESTIGATOR: WENDY PARULEKAR

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To interpret and address, through clinical and translational research, the disease burden associated with head and neck malignancies in Canada.
- To review recent developments in the understanding of molecular biology and new therapeutics as these relate to head and neck malignancies.
- To update, review, and discuss recent results of clinical studies conducted by the Canadian Cancer Trials Group or its collaborators.
- To provide a learning environment supportive to new investigators.

10:00 am	<u>Welcome</u>	John Waldron
	<u>New Concepts/Proposals</u>	
10:10 am	Immune Score Prognostic Marker Initiated Radiation de-Escalation (INSPIRE) for HPV-positive OPSCC (INSPIRE)	Anthony Nichols and David Palma
	<u>Update on Approved Ongoing Proposals</u>	
10:25 am	HN.13 - Optimizing head and Neck Tumour And Symptom Control in Patients Unable to Tolerate Curative Intent RT: a Phase III trial Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study)	Ian Poon
10:40 am	HN.12 - Promote-HN- PembROlizumab with or without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma	Anna Spreafico
10:55 am	HN.11- SPECT-CT Guided ELE ctive Con tralateral Neck Treatment in Lateralized Oropharynx Cancer (SELE CT): For Patients with Lateralized Oropharyngeal Cancer: A Phase III Randomized Controlled Trial	John de Almeida and Ali Hosni
11:10 am	HN.10- A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma	Scott Bratman

11:25 am	HN.9- Randomized Phase II Study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab versus Durvalumab plus Radiotherapy followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC)	Khalil Sultanem
11:40 am	HNC.2 (NRG-HN004) - Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin	Eric Winquist
11:55 pm	<u>Canadian Cancer Society Grant Update</u>	Wendy Parulekar
12:10 pm	<u>Disease Site Committee Co-Chair Announcement</u>	Wendy Parulekar and John Waldron
12:20 pm	<u>Other Business</u>	
12:30 pm	<u>Lunch Break</u>	
	<u>Guest Speaker</u>	
1:00 pm	Directions for the Head and Neck Cancer Portfolio at NRG Oncology	Sue Yom
2:00 pm	<u>Meeting Adjourned</u>	